q&more
My watch list
my.chemie.de  
Login  
Translation

Translation

Innovations from the lab to commercial application

Prof. Dr. Arne Skerra (Technische Universität München, Lehrstuhl für Biologische Chemie)

The structure of the big chemical and pharmaceutical companies has changed. Traditional centralised research departments conducting fundamental research have fallen victim to economic considerations. In exchange, young, dynamic start-up enterprises are increasingly brightening up the scene. This boosts the development of new international co-operation models for the conversion of scientific ideas and findings into new products.

The biotech industry has developed into an established sector in Germany, among other countries; its business ideas originate primarily from universities or research institutes, which are put into practice by young scientists. Assisted by management and business plan seminars, the foundation of companies has become a serious alternative for bioscience graduates to conventional professional careers which have become increasingly rare due to the structural change in the industry. Public promotion programmes such as GO-Bio, EXIST and FLÜGGE support such initiatives at different stages.

This trend is progressively spilling over into other areas in chemistry, physics and engineering for which – considering the innovation and human potential – similarly fertile conditions are found at the universities. Admittedly, long time lines and high development effort as well as significant production costs are to be balanced against a highly variable intrinsic product value. In the case of biotech companies, the guarantee for return on investment is generally the prospect of later clinical approval for a lucrative blockbuster drug. This is in stark contrast to bulk production in the chemical industry: large-scale manufacturing of chemicals and polymers seen against low profit margins and high capital expenditure for technical equipment.

Nevertheless, this sector also offers opportunities for added value through highly innovative processes and/or refined goods and a business to business (B2B) model. Generating new know-how and patents is the actual
value driver for such start-up companies and gives them a right to exist beside large enterprises which increasingly focus on regulatory aspects (technical safety, regulatory approval), mass production for end consumers as well as sales and marketing. The high dynamics of innovation in a flat-hierarchy, highly flexible and pragmatic environment have led to a profitable job sharing between the biotech start-up scene and the pharmaceutical industry, for example. However, two aspects deserve attention in order not to hamper this ongoing development.

On the one hand, there is an early stage financing problem for advancing innovations by newly-formed companies. The gap between the seed phase, mostly financed by public funding bodies, and the start-up phase, which is focused on product development and expansion, has grown in the past few years. New mechanisms of co-operation between venture capital (VC) companies and private investors need to be found. While for the former an investment only attracts interest as from a certain financing volume and an already calculable stage of development of the technical innovation, the latter frequently take a higher risk and are more guided by the founders‘ personality; yet it is less of an incentive if private investors – including the founders of the company – get marginalised by venture capital in the course of subsequent financing rounds.

On the other hand, university intellectual property (IP) management requires overhauling. Although today most universities have their own technology transfer agencies and inventor offices, processes are frequently unduly bureaucratic and subject to unrealistic expectations of early profits. The revision of the German Employee Invention Act of 2002, which deprived university employees of their independence as inventors, was rather counter-productive. The majority of university IP – in contrast to technologically more focused large research organisations such as the Max Planck Society or Helmholtz Association –  comprises a wide range of single highly innovative discoveries/developments, with most of them still premature for application. Turning this strongly polarised opportunity/risk ratio into a sustainable innovation requires a high level of personal commitment in combination with entrepreneurial skills, where complex decision-making processes turn out to be obstructive.

Need for action has been recognized in these areas, and one can hope that the translation of results from fundamental university research into economic practice will further grow in efficiency, especially in a country
that highly depends on technological development.

First publication: Skerra, A., q&more, 2.2011.

Facts, background information, dossiers

  • intellectual proper…
  • early stage financing

More about TU München

  • News

    ClpX-ClpP protein complex could be starting point for new antibiotics

    Antibiotics are still the most important weapon for combatting bacterial infections. But medical science is running out of “ammunition” because of more and more frequently occurring resistances. A research team has now elucidated the structure of the proteolytic complex ClpX-ClpP. This is a ... more

    Light in the nanoworld

    An international team headed up by Alexander Holleitner and Jonathan Finley, physicists at the Technical University of Munich (TUM), has succeeded in placing light sources in atomically thin material layers with an accuracy of just a few nanometers. The new method allows for a multitude of ... more

    Activity of fuel cell catalysts doubled

    An interdisciplinary research team at the Technical University of Munich (TUM) has built platinum nanoparticles for catalysis in fuel cells: The new size-optimized catalysts are twice as good as the best process commercially available today. Fuel cells may well replace batteries as the powe ... more

  • q&more articles

    Diet, gut microbiota and host lipid metabolism

    Nature provides an enormous diversity of lipid molecules that originate from various pathways. Fatty acids are key modules for various lipids, including cell membrane lipids such as phospholipids or triacylglycerols, which are the major components of lipid droplets. Excess lipids or defects ... more

  • Authors

    Dr. Josef Ecker

    Josef Ecker, born in 1978, studied biology at the University of Regensburg. He earned his doctorate in 2007, after which he researched as a postdoc at the University Hospital in Regensburg at the Institute of Clinical Chemistry. After several subsequent years in industry, working in executi ... more

    Prof. Dr. Arne Skerra

    Arne Skerra, born in 1961, studied chemistry at the Technical University of Darmstadt and obtained his doctoral degree as Dr. rer. nat. at the Gene Center of the Ludwig-Maximilians Univer­sity Munich in 1989. After staying at the MRC Laboratory of Molecular Biology in Cambridge, UK, and the ... more

    Dr. Thomas Letzel

    Thomas Letzel, born 1970, studied chemistry (1992–1998) at the TU Muenchen and the LMU Muenchen. He acquired his doctorate in 2001 with an environmental-analytical subject at the TU Muenchen, followed by a two years' postdoc stay at the Vrijen Universiteit Amsterdam. He qualified as a profe ... more

White paper

Product

Most widely read

  1. Quality assurance in medical laboratories
  2. Drug substances in the drug product dossier
  3. Surprisingly simple molecules as potential OLED-Emitters?
  4. Accurate weighing results
  5. New Requirements
  6. From Weight to Volume
  7. Learning from insects
  8. Oligomers in polyester-based food packaging
  9. Weighing in the US Pharmacopeia
  10. More than honey?

Topics A-Z

All topics

q&more – the networking platform for quality excellence in lab and process

The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.

> more about q&more

q&more is supported by:

 

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE